Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 - Episode 15
EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates
The expert panel explores the future landscape of lower-risk myelodysplastic syndrome treatment, considering recent approvals and emerging clinical data.
Video Player is loading.
Video content above is prompted by the following
- What does the future of lower-risk MDS treatment look like?
- Following the latest approvals, guideline updates, and emerging data:
- How does this impact your future treatment strategies?
- Following the latest approvals, guideline updates, and emerging data:
Related Content:
